Treatment of HBeAg negative chronic hepatitis B with new drugs (adefovir and others).
Hadziyannis
Stephanos J
SJ
Department of Medinine and Hepatology, Henry Dunant Hospital, 107 Messogion Avenue, Athens, Greece. hadziyannis@ath.forthnet.gr
Papatheodoridis
George V
GV
D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D001086:Arabinofuranosyluracil / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068679:Emtricitabine; D006147:Guanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006513:Hepatitis B e Antigens / Q000032:analysis*; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D009705:Nucleosides / Q000627:therapeutic use; D063065:Organophosphonates
D000998:Antiviral Agents; D006513:Hepatitis B e Antigens; D009705:Nucleosides; D063065:Organophosphonates; D003841:Deoxycytidine; D001086:Arabinofuranosyluracil; C413685:entecavir; D006147:Guanine; C053001:adefovir; D000068679:Emtricitabine; C034935:clevudine; D000225:Adenine